Literature DB >> 11677131

Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A.

A McCluskey1, C Walkom, M C Bowyer, S P Ackland, E Gardiner, J A Sakoff.   

Abstract

Cantharidin and its analogues have been of considerable interest as potent inhibitors of the serine/threonine protein phosphatases 1 and 2A (PP1 and PP2A). However, limited modifications to the parent compounds is tolerated. As part of an on-going study we have developed a new series of cantharidin analogues, the cantharimides. Inhibition studies indicate that cantharimides possessing a D- or L-histidine, are more potent inhibitors of PP1 and PP2A (PP1 IC(50)=3.22+/-0.7 microM; PP2A IC(50)=0.81+/-0.1 microM and PP1 IC(50)=2.82+/-0.6 microM; PP2A IC(50)=1.35+/-0.3 microM, respectively) than norcantharidin (PP1 IC(50)=5.31+/-0.76 microM; PP2A IC(50)=2.9+/-1.04 microM) and essentially equipotent with cantharidin (PP1 IC(50)=3.6+/-0.42 microM; PP2A IC(50)=0.36+/-0.08 microM). Cantharimides with non-polar or acidic amino acid residues are only poor inhibitors of PP1 and PP2A.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11677131     DOI: 10.1016/s0960-894x(01)00594-7

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

1.  Norcantharidin-induced apoptosis is via the extracellular signal-regulated kinase and c-Jun-NH2-terminal kinase signaling pathways in human hepatoma HepG2 cells.

Authors:  Yan-Nian Chen; Chi-Chih Cheng; Jung-Chou Chen; Wei Tsauer; Shih-Lan Hsu
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

2.  Activation of Na+/H+ exchange by protein phosphatase inhibitors in red blood cells of the frog Rana ridibunda.

Authors:  G P Gusev; T I Ivanova
Journal:  J Comp Physiol B       Date:  2003-05-20       Impact factor: 2.200

3.  Crystal structures and mutagenesis of PPP-family ser/thr protein phosphatases elucidate the selectivity of cantharidin and novel norcantharidin-based inhibitors of PP5C.

Authors:  Debasish Chattopadhyay; Mark R Swingle; Edward A Salter; Eric Wood; Brandon D'Arcy; Catherine Zivanov; Kevin Abney; Alla Musiyenko; Scott F Rusin; Arminja Kettenbach; Larry Yet; Chad E Schroeder; Jennifer E Golden; Wade H Dunham; Anne-Claude Gingras; Surajit Banerjee; David Forbes; Andrzej Wierzbicki; Richard E Honkanen
Journal:  Biochem Pharmacol       Date:  2016-03-23       Impact factor: 5.858

4.  Small-molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating Sonic hedgehog signaling in human breast cancer cells.

Authors:  Yu-Jen Chen; Cheng-Deng Kuo; Szu-Han Chen; Wei-Jen Chen; Wen-Chien Huang; K S Clifford Chao; Hui-Fen Liao
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

5.  Facile Chemical Access to Biologically Active Norcantharidin Derivatives from Biomass.

Authors:  Konstantin I Galkin; Fedor A Kucherov; Oleg N Markov; Ksenia S Egorova; Alexandra V Posvyatenko; Valentine P Ananikov
Journal:  Molecules       Date:  2017-12-12       Impact factor: 4.411

6.  N-Farnesyloxy-norcantharimide inhibits progression of human leukemic Jurkat T cells through regulation of mitogen-activated protein kinase and interleukin-2 production.

Authors:  Ming-Che Chang; Jin-Yi Wu; Hui-Fen Liao; Yu-Jen Chen; Cheng-Deng Kuo
Journal:  Anticancer Drugs       Date:  2015-11       Impact factor: 2.248

7.  Effective Material Basis and Mechanism Analysis of Compound Banmao Capsule against Tumors Using Integrative Network Pharmacology and Molecular Docking.

Authors:  Tian-Mu He; Jing-Xian Liu; Can-Can Duan; Xiao-Fei Li; Jian-Yong Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-04       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.